Skip to main content

Cancer Immunology, Immunotherapy

Ausgabe 8/2023

Inhalt (27 Artikel)

Open Access Research

Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway

Jonas Althaus, Verena Nilius-Eliliwi, Abdelouahid Maghnouj, Sascha Döring, Roland Schroers, Michael Hudecek, Stephan A. Hahn, Thomas Mika

Research

Characteristic differences in the abundance of tumor-infiltrating lymphocytes and intratumoral developing T cells in thymoma, with special reference to PD-1 expression

Tatsuo Furuya, Shunta Ishihara, Hiroshi Ogi, Kyoko Masuda, Saya Shibata, Chiaki Nakazono, Satoru Okada, Masanori Shimomura, So Tando, Takeshi Yaoi, Yoshinobu Maeda, Masaaki Yamagishi, Hiroshi Kawamoto, Kyoko Itoh, Masayoshi Inoue

Research

Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations

Yukiko Shimoda, Tatsuya Yoshida, Jun Miyakoshi, Masahiro Torasawa, Akiko Tateishi, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe

Open Access Research

Switchable CAR T cell strategy against osteosarcoma

Laura Hidalgo, Beatriz Somovilla-Crespo, Patricia Garcia-Rodriguez, Alvaro Morales-Molina, Miguel Angel Rodriguez-Milla, Javier Garcia-Castro

Research

The pathogenetic significance of exhausted T cells in a mouse model of mature B cell neoplasms

Asuka Shibamiya, Yurie Miyamoto-Nagai, Shuhei Koide, Motohiko Oshima, Ola Rizq, Kazumasa Aoyama, Yaeko Nakajima-Takagi, Rei Kato, Kensuke Kayamori, Yusuke Isshiki, Nagisa Oshima-Hasegawa, Tomoya Muto, Shokichi Tsukamoto, Yusuke Takeda, Ryo Koyama-Nasu, Tetsuhiro Chiba, Hiroaki Honda, Koutaro Yokote, Atsushi Iwama, Emiko Sakaida, Naoya Mimura

Research

Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas

E. Toulemonde, S. Chevret, M. Battistella, E. M. Neidhardt, C. Nardin, F. Le Du, N. Meyer, M. Véron, L. Gambotti, A. Lamrani-Ghaouti, P. Jamme, C. Chaffaut, M. De Pontville, E. Saada-Bouzid, M. Beylot-Barry, C. Simon, T. Jouary, A. Marabelle, L. Mortier

Open Access Research

Characterizing the tumor immune microenvironment of ependymomas using targeted gene expression profiles and RNA sequencing

W. de Koning, F. F. Feenstra, F. G. J. Calkoen, J. van der Lugt, L. A. Kester, D. A. M. Mustafa

Research

Phenotypic and functional analysis in HER2+ targeted therapy of human NK cell subpopulation according to the expression of FcεRIγ and NKG2C in breast cancer patients

María B. Bordignon, Ayelén I. Pesce Viglietti, Estefanía P. Juliá, María B. Sanchez, Alexander Rölle, Pablo Mandó, Luciana Sabatini, Alexis Ostinelli, Manglio M. Rizzo, María M. Barrio, José Mordoh, Leonardo Fainboim, Estrella M. Levy

Open Access Research

Identification of a novel immune checkpoint molecule V-set immunoglobulin domain-containing 4 that leads to impaired immunity infiltration in pancreatic ductal adenocarcinoma

Yongsheng Jiang, Lijie Han, Jian Yang, Minwei Yang, Jian Zhang, Meilin Xue, Youwei Zhu, Cheng Xiong, Minmin Shi, Shiwei Zhao, Baiyong Shen, Zhiwei Xu, Lingxi Jiang, Hao Chen

Research

Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1/PD-L1 blockade therapy

Yusuke Inoue, Naoki Inui, Masato Karayama, Kazuhiro Asada, Masato Fujii, Shun Matsuura, Tomohiro Uto, Dai Hashimoto, Takashi Matsui, Masaki Ikeda, Hideki Yasui, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Noriyuki Enomoto, Tomoyuki Fujisawa, Takafumi Suda

Research

Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma

Qi Zhang, Jian Zhang, Haijun Zhong, Ying Yuan, Lei Yang, Qingyuan Zhang, Dongmei Ji, Jifang Gong, Jing Li, Zhenling Yao, Chuan Qi, Jianming Wang, Lingmin Lu, Michael Shi, Xueming Qian, Lin Shen, Jian Li, Xichun Hu

Research

Self-assembled nanoparticles based on DNA origami and a nitrated T helper cell epitope as a platform for the development of personalized cancer vaccines

Yanliang Kang, Wanli Zhang, Qiumin Yu, Le Gao, Jiale Quan, Fangling Gu, Yuxin Wu, Yahong Tian, Zijie Wu, Shishuai Shao, Hongyou Zhou, Shukang Duan, Yixiang Zhou, Li Zhang, Xiangdong Gao, Hong Tian, Wenbing Yao

Open Access Research

Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing

Sung Ill Jang, Hyung Keun Lee, Eun-Ju Chang, Somi Kim, So Young Kim, In Young Hong, Jong Kyoung Kim, Hye Sun Lee, Juyeon Yang, Jae Hee Cho, Dong Ki Lee

Research

Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent + CAG regimen in patients with relapsed/refractory acute myeloid leukemia

Xiao-Ning Gao, Yong-Feng Su, Meng-yue Li, Yu Jing, Jun Wang, Lei Xu, Lin-Lin Zhang, An Wang, Yi-Zhi Wang, Xuan Zheng, Yan-Fen Li, Dai-Hong Liu

Open Access Research

Exploiting docetaxel-induced tumor cell necrosis with tumor targeted delivery of IL-12

S. Elizabeth Franks, Ginette S. Santiago-Sanchez, Kellsye P. Fabian, Kristen Solocinski, Paul L. Chariou, Duane H. Hamilton, Joshua T. Kowalczyk, Michelle R. Padget, Sofia R. Gameiro, Jeffrey Schlom, James W. Hodge

Research

Brachyury-targeted immunotherapy combined with gemcitabine against head and neck cancer

Hidekiyo Yamaki, Michihisa Kono, Risa Wakisaka, Hiroki Komatsuda, Takumi Kumai, Ryusuke Hayashi, Ryosuke Sato, Toshihiro Nagato, Takayuki Ohkuri, Akemi Kosaka, Kenzo Ohara, Kan Kishibe, Miki Takahara, Tatsuya Hayashi, Hiroya Kobayashi, Akihiro Katada

Open Access Research

Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology

Usman Y. Panni, Michael Y. Chen, Felicia Zhang, Darren R. Cullinan, Lijin Li, C. Alston James, Xiuli Zhang, S. Rogers, A. Alarcon, John M. Baer, Daoxiang Zhang, Feng Gao, Christopher A. Miller, Qingqing Gong, Kian-Huat Lim, David G. DeNardo, S. Peter Goedegebuure, William E. Gillanders, William G. Hawkins

Research

Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors

Hidetomo Himuro, Yoshiro Nakahara, Yuka Igarashi, Taku Kouro, Naoko Higashijima, Norikazu Matsuo, Shuji Murakami, Feifei Wei, Shun Horaguchi, Kayoko Tsuji, Yasunobu Mano, Haruhiro Saito, Koichi Azuma, Tetsuro Sasada

Open Access Research

Sequential CAR T cell and targeted alpha immunotherapy in disseminated multiple myeloma

Dennis Awuah, Megan Minnix, Enrico Caserta, Theophilus Tandoh, Vikram Adhikarla, Erasmus Poku, Russell Rockne, Flavia Pichiorri, John E. Shively, Xiuli Wang

Open Access Research

Enhanced HPV16 E6/E7+ tumor eradication via induction of tumor-specific T cells by therapeutic vaccination with virosomes presenting synthetic long peptides

Toon Stegmann, Anna-Sophia Wiekmeijer, Kitty Kwappenberg, Suzanne van Duikeren, Farien Bhoelan, Denzel Bemelman, Thomas J. M. Beenakker, Willem-Jan Krebber, Ramon Arens, Cornelis J. M. Melief

Open Access Brief Report

Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide

Tomoki Naoe, Akiko Saito, Nahoko Hosono, Senji Kasahara, Hideharu Muto, Kaoru Hatano, Mizuki Ogura, Taro Masunari, Masatsugu Tanaka, Kensuke Usuki, Yuichi Ishikawa, Koji Ando, Yukio Kondo, Yusuke Takagi, Satoru Takada, Maho Ishikawa, Ilseung Choi, Akihiro Sano, Hirokazu Nagai

Correction

Correction to: Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis

Guanfang Liu, Qi Zhang, Jingying Yang, Xiaomin Li, Luhua Xian, Wenmin Li, Ting Lin, Juan Cheng, Qiwen Lin, Xiuzhang Xu, Qin Li, Yu Lin, Maohua Zhou, Erxia Shen

Correction

Correction to: IL‑17A promotes fatty acid uptake through the IL‑17A/IL‑17RA/ p‑STAT3/FABP4 axis to fuel ovarian cancer growth in an adipocyte‑rich microenvironment

Chunyan Yu, Xiulong Niu, Yongrui Du, Yan Chen, Xiaomei Liu, Lingling Xu, Yoichiro Iwakura, Xiaoxia Ma, Yan Li, Zhi Yao, Weimin Deng

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.